207_Combined course Presentations

Nivolumab for previously treated unresectable metastatic anal cancer

Phase II trial (NCT02314169) • Inclusion: previously-treated metastatic patients • Primary Endpoint: Tumor response (RECIST 1.1) Results: • Response in 9 of 37 patients (24%; CR in n=2) • Median OS: 11.5 months; median PFS: 4.1 months • Good toxicity profile, no SAEs

Higher immunogenicity Better response

Morris et al, Lancet Oncolology 20